VS 7375
Alternative Names: GFH-375; GFH375/VS-7375; VS-7375Latest Information Update: 21 Aug 2025
At a glance
- Originator GenFleet Therapeutics
- Developer GenFleet Therapeutics; Verastem Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 13 Aug 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours released by Verastem Oncology
- 24 Jul 2025 VS 7375 receives Fast track designation status for Adenocarcinoma (First-line therapy, Late-stage disease, Metastatic disease) in USA
- 24 Jul 2025 VS 7375 receives Fast track designation status for Adenocarcinoma (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA